Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera

Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal trials. Fourteen cases of tuberculosis have since b...

Full description

Bibliographic Details
Main Authors: Sylvain Lescuyer, Marie-Pierre Ledoux, Simon Gravier, Shanti Natarajan-Amé, Céline Duval, Fréderic Maloisel, Laurent Mauvieux, Elise Toussaint, Luc-Matthieu Fornecker, Raoul Herbrecht
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971219300128

Similar Items

Similar Items